Article Listing - Eli Lilly's 2nd-qtr EPS increases 17%
HOECHST DEFENDS NOMIFENSINE IN SUIT
16 March 1992
The German drugs major Hoechst AG is defending itself against allegations linked to claimed side effects of the company's antidepressant...
ARES-SERONO Rx DRUG SALES UP 15.5%
16 March 1992
On group sales of $751.1 million for the year ended December 31, 1991 (reported in brief last week), Swiss-based Ares-Serono...
MEVACOR WORKS IN FDB, SAYS STUDY
16 March 1992
Familial defective apolipoprotein B-100 (FDB), an autosomal dominant disorder characterized by hyper-cholesterolemia, has been shown to be responsive to treatment...
US ORPHAN DRUG CHANGE "WOULD BE VETOED"
16 March 1992
The US Bush Administration is strongly opposed to S 2060, the Senate legislation which proposes to end the market monopoly...
HANTAREX BIOMED LINK WITH SMA?
16 March 1992
A new alliance with possible developments in the biomedical sector has been set up recently in Italy. Under a preliminary...
LIFEGrOUP CHANGES ACQUISITION PLAN
16 March 1992
After a long period of analysis and negotiation, Italy's LIFEGROUP, founded in 1991, has decided against proceeding with the planned...
BEECHAM WITHDRAWS TALPEN FROM UK
16 March 1992
- Beecham Pharma has withdrawn the broad spectrum penicillin antibiotic Talpen (talampicillin hydrochloride) from the UK market on grounds that...
BBG'S DETECTION KITS
16 March 1992
- British Bio-technology Prod-ucts Ltd has expanded its range of in situ hybridization products to include a Detection Module for...
TREATMENT IND FOR AGOURON'S AG-331
16 March 1992
- Oncologists have confirmed that USA-based Agouron Phar-ma's AG-331 has been effective against tumors in animals. The company plans to...
GENZYME AND GLYCOPROTEINS
16 March 1992
- Genzyme Corp, in collaboration with Robert Van Etten and colleagues at Purdue University, Indiana, has developed technol-ogy which could...
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
